Stockreport

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF Deep and durable responses observed in a heavily pretreated, historically immunotherapy-resistant populationFindings reinforce the broad, pan-tumor activity of BOT+BAL a [Read more]